Your browser doesn't support javascript.
loading
New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil.
Goes, Livia R; Siqueira, Juliana D; Garrido, Marianne M; Alves, Brunna M; Pereira, Ana Cristina P M; Cicala, Claudia; Arthos, James; Viola, João P B; Soares, Marcelo A.
Afiliação
  • Goes LR; Oncovirology Program, Brazilian National Cancer Institute, Rua Andre Cavalcanti, 37, Rio de Janeiro, RJ 20231-050, Brazil; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Building 10 Room 6A08, 9000 Rockville Pike, Bethesda, MD 20892, USA. Electronic address: l
  • Siqueira JD; Oncovirology Program, Brazilian National Cancer Institute, Rua Andre Cavalcanti, 37, Rio de Janeiro, RJ 20231-050, Brazil. Electronic address: juliana.siqueira@inca.gov.br.
  • Garrido MM; Hospital Infection Control Committee, Brazilian National Cancer Institute, Praça Cruz Vermelha, 23, Rio de Janeiro, RJ 20230-130, Brazil. Electronic address: Marianne.Monteiro@inca.gov.br.
  • Alves BM; Oncovirology Program, Brazilian National Cancer Institute, Rua Andre Cavalcanti, 37, Rio de Janeiro, RJ 20231-050, Brazil. Electronic address: brunnamisael@gmail.com.
  • Pereira ACPM; Section of Anesthesiology, Brazilian National Cancer Institute, Praça Cruz Vermelha, 23, Rio de Janeiro, RJ 20230-130, Brazil. Electronic address: ana.pinho@inca.gov.br.
  • Cicala C; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Building 10 Room 6A08, 9000 Rockville Pike, Bethesda, MD 20892, USA. Electronic address: ccicala@niaid.nih.gov.
  • Arthos J; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Building 10 Room 6A08, 9000 Rockville Pike, Bethesda, MD 20892, USA. Electronic address: jarthos@niaid.nih.gov.
  • Viola JPB; Program of Immunology and Tumor Biology, Brazilian National Cancer Institute, Rua Andre Cavalcanti, 37, Rio de Janeiro, RJ 20231-050, Brazil. Electronic address: jpviola@inca.gov.br.
  • Soares MA; Oncovirology Program, Brazilian National Cancer Institute, Rua Andre Cavalcanti, 37, Rio de Janeiro, RJ 20231-050, Brazil; Department of Genetics, Federal University of Rio de Janeiro, Av. Carlos Chagas Filho, 373, Rio de Janeiro, RJ 21941-590, Brazil. Electronic address: masoares@inca.gov.br.
Infect Genet Evol ; 94: 104998, 2021 10.
Article em En | MEDLINE | ID: mdl-34252616
ABSTRACT
After a one-year rollout of the pandemic caused by SARS-CoV-2, the continuous dissemination of the virus has generated a number of variants with increased transmissibility and infectivity, called variants of concern (VOC), which now predominate worldwide. Concerns about the susceptibility of humans that have already been infected before or those already vaccinated to infection by VOC rise among scientists and clinicians. Herein, we assessed the prevalence of different VOC among recent infections at the Brazilian National Cancer Institute (Rio de Janeiro, Brazil). By using a Sanger-based sequencing approach targeting the viral S gene to identify VOC, we have analyzed 72 recent infections. The overall prevalence of VOC was 97%. Among the subjects analyzed, six had been vaccinated with the ChAdOx1-S/nCoV-19 (n = 4; one with two doses and three with one dose) or the CoronaVac (n = 2; both with 2 doses) vaccine, while five subjects represented reinfection cases, being two of them also part of the vaccinated group (each one with one vaccine type). All vaccinated and re-infected subjects carried VOC irrespective of the vaccine type taken, the number of doses taken, IgG titers or being previously infected during the first wave of the Brazilian pandemic. Importantly, all six vaccinees only had mild symptoms. We present here several examples of how natural infections or vaccination may not be fully capable of conferring sterilizing immunity against VOC.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Glicoproteína da Espícula de Coronavírus / Vacinas contra COVID-19 / SARS-CoV-2 / COVID-19 Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Humans País/Região como assunto: America do sul / Brasil Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Glicoproteína da Espícula de Coronavírus / Vacinas contra COVID-19 / SARS-CoV-2 / COVID-19 Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Humans País/Região como assunto: America do sul / Brasil Idioma: En Ano de publicação: 2021 Tipo de documento: Article